EDO-S101 (Tinostamustine) is a fusion molecule comprising of the alkylator bendamustine and the HDAC-inhibitor vorinostat.
EDO-S101 (Tinostamustine) displays potent activity in vitro in MM cell lines (IC50=1.6-4.8 uM) and ex vivo in cells isolated from MM patients.
EDO-S101 (Tinostamustine) shows activity in CB17-SCID murine plasmacytoma model and in de novo Vk*MYC mice, also is the only drug with single-agent activity in the multidrug resistant Vk12653 murine model.
